{"name":"Oblato, Inc.","slug":"oblato-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"OKN-007","genericName":"OKN-007","slug":"okn-007","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"OKN-007","genericName":"OKN-007","slug":"okn-007","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPUGZEY2JIYWN3Y2dqeF9RYmtwWlBqa3Nxd1RodUNNOGI3THlfbzBLLVNGaUV1ZXZXMlkzTzluYmFBbzZnckdOSFd0NktuRUFLZkhvOWlwZWJTUkxSaDRfSkUyanFyWndvRnF3aTdJRjhIZWVabkE2NVJaZVNaaEJjeFc0dGIycnktSENVZTJOSGp0aFdxNzRNOEF5a0xOeGRJd01SLVBVTXR2bzNBU2xMYjhqVVMyU1lUOFE5Tzd6ellITkhqcUs3NHVwcEVOTUI5UHFZTTRiU3EtLU1OVkpOanZnVzVBa3lRaDA2X3hYUUtUM3ZqYWFScjFn?oc=5","date":"2026-03-21","type":"trial","source":"Barchart.com","summary":"Recurrent Glioblastoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight - Barchart.com","headline":"Recurrent Glioblastoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOZmJEeS1EbndQWGpSczlMd0Q2dlB3QkJDWUVtaG1nT2ZXUHZ3TUoyR1BGTHctN2lMblNPWk9ITmdGR1hFRXhqcXFPd2pteXA0ajQwOHQ3M1lWcGpvcnpDcV9ZbGx6bEREOWc2cjBQSVRsTHZGZEI5bmxjSHdOTHdYVm13X1VRSHFFa0FobXFTQzNDN25iQkFpUmxwNV9xdw?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"High-Grade Glioma Treatment Pipeline Shows Strong Momentum as - openPR.com","headline":"High-Grade Glioma Treatment Pipeline Shows Strong Momentum as","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-27","type":"trial","source":"GlobeNewswire","summary":"Glioblastoma Market, an Area With High Trial Failure And - GlobeNewswire","headline":"Glioblastoma Market, an Area With High Trial Failure And","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBCbmZnTm0wWU9tY0d3MFhWNkdvYTR0ckJtaEstaVZpQkdhQ2lieDczWWFST3pySWo5NktsWmxyVFJ6ejZaWGxjbk9LVlVmM0swSG9Pb0ZoWnVKTVV3SWYxb2dMVllnM2U5QnpiMzln0gFyQVVfeXFMUG5RdF9lUUNNb3VLZ2x5dDlXOE15NDVraXNxRmJtOUVzS1NLZzVvb3B6WWh4UVg5MWNMY1dQMmVHdXNPekpTampuLWJkWjlIdFh1TmNiSUJycnRzMGZiVGhiSWwwM1h0amw0QS1rOEhVWThB?oc=5","date":"2021-11-26","type":"regulatory","source":"koreabiomed.com","summary":"FDA OKs expanded access program for HLB Therapeutics' tinnitus treatment candidate - koreabiomed.com","headline":"FDA OKs expanded access program for HLB Therapeutics' tinnitus treatment candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE9mWWV0OFVUZElBRkZfc1lEWWZlcnd5S2I3V2tRSGFTOEt4REhFMTlwVUxCUk0wTzQxaVB2cTdPWmF2ZmRST2dzNHJJYTl5Z3l4WmhVal9kZGVZbnB6VmxPRmgyaw?oc=5","date":"2020-02-12","type":"deal","source":"The Hearing Review","summary":"Oblato Acquires Rights to Hearing Loss Drug - The Hearing Review","headline":"Oblato Acquires Rights to Hearing Loss Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOSDdsckkxVDE2OXZzVUFDTFpjRzNyQ29UZkg2RHJVQUZhM0otWVhKa1BiTWlZdVB0Zjh3YXBmMV9ubUJkckoySEdiT2U0WGNMaUh4dGZBczk1N3Vrd19LWXZfY21Ldk4yUEtKb2ZoMWlOX2FkNkFmdjFaZF9nNTZPQno5Qy1IT1lTOHVXdGhnaVh5cm5yT1RpS0MyNFZBTDhWSDlJTFBoOW9PVWNXRVFNLTYxVTNSRFNpTVpDRVpXS1Y2RkZTVEEzYg?oc=5","date":"2020-02-11","type":"deal","source":"OKC VeloCity","summary":"Biotech company acquires hearing loss drug discovered by Hough Ear Institute scientists - OKC VeloCity","headline":"Biotech company acquires hearing loss drug discovered by Hough Ear Institute scientists","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}